The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 22, 2020

Filed:

Oct. 06, 2016
Applicant:

University of Virginia Patent Foundation, Charlottesville, VA (US);

Inventors:

Bijan K. Dey, Slingerlands, NY (US);

Paul Andrew Yates, Charlottesville, VA (US);

Assignee:

University of Virginia Patent Foundation, Charlottesville, VA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01); A61K 31/7088 (2006.01); C12Q 1/6883 (2018.01); A61K 31/7125 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 9/0048 (2013.01); A61K 31/7088 (2013.01); A61K 31/7125 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/113 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/3517 (2013.01); C12N 2320/32 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01);
Abstract

The application discloses compositions and methods for preventing and treating diabetic retinopathy. It is disclosed herein that an inhibitor of microRNA-let-7b administered to the eye of a subject in need thereof is useful for preventing and treating several problems associated with diabetic retinopathy and plays a role in vasculature stabilization, increasing retinal thickness, reducing retinal capillary dropout, diminishing microvascular leakage, preventing or treating hyperproliferation of microvascular cells, and stabilizing aberrant neovascularization. The invention includes the use of various kinds of inhibitors of microRNA-let-7b, including, but not limited to, an antagomir of miRNA-let-7b. A useful compound of the invention can be administered into the eye, including intravitreally. A useful antagomir is Dy547-mA(*)mA(*)mCmCmAmCmAmCmAmAmCmCmUmAmCmUmAmCmCmU(*) mC(*)mA (*)(3'-Chl).


Find Patent Forward Citations

Loading…